The FreeStyle Precision Pro system from Abbott allows providers to test blood glucose levels with individually-wrapped test strips, the company said.
The Department of Justice and Abbott Laboratories agreed to a $5.48 million settlement on Dec. 27 related to allegations that physicians received kickbacks for pushing stents.
Federal regulators approved Pfizer's new Xeljanz treatment for rheumatoid arthritis Tuesday. The potentially lucrative drug is now poised to enter a market that already features Humira, Abbott Laboratories' top-selling rheumatoid arthritis treatment.
Abbott Laboratories will pay $1.5 billion over allegations that it improperly promoted the anti-seizure drug Depakote for dementia care. The firm also reportedly paid kickbacks to physicians and long-term pharmacists to encourage its off-label use, according to court records. The case includes a criminal fine and forfeiture of $700 million and civil settlements with the federal government and states totaling $800 million. The company also agreed to enter a five-year probationary period.
The National Institutes of Health announced it is ending its study of the cholesterol drug Niaspan 18 months early. Tracking results showed the medication had almost no chance of being beneficial to patients, researchers found.